GPGlauce Regina Pigatto

Glauce Regina Pigatto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Glauce Regina Pigatto has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling

    by Carlos Wagner S. Wanderley, Alexandre G.M. Maganin, Beatriz Adjafre, Atlante S. Mendes, Conceição Elidianne Anibal Silva, Andreza Urba Quadros, João Paulo Mesquita Luiz, Camila Meirelles S. Silva, Nicole R. Silva, Francisco Fabio Bezerra Oliveira, et al.

    Supplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling

  • Open Access

    Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling

    by Carlos Wagner S. Wanderley, Alexandre G.M. Maganin, Beatriz Adjafre, Atlante S. Mendes, Conceição Elidianne Anibal Silva, Andreza Urba Quadros, João Paulo Mesquita Luiz, Camila Meirelles S. Silva, Nicole R. Silva, Francisco Fabio Bezerra Oliveira, et al.

    Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling


  • Open Access

    Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling

    by Carlos Wagner S. Wanderley, Alexandre G.M. Maganin, Beatriz Adjafre, Atlante S. Mendes, Conceição Elidianne Anibal Silva, Andreza Urba Quadros, João Paulo Mesquita Luiz, Camila Meirelles S. Silva, Nicole R. Silva, Francisco Fabio Bezerra Oliveira, et al.

    Supplementary Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling

  • Open Access

    Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling

    by Carlos Wagner S. Wanderley, Alexandre G.M. Maganin, Beatriz Adjafre, Atlante S. Mendes, Conceição Elidianne Anibal Silva, Andreza Urba Quadros, João Paulo Mesquita Luiz, Camila Meirelles S. Silva, Nicole R. Silva, Francisco Fabio Bezerra Oliveira, et al.

    Cytotoxic agents synergize with immune checkpoint inhibitors and improve outcomes for patients with several cancer types. Nonetheless, a parallel increase in the incidence of dose-limiting side effects, such as peripheral neuropathy, is often observed. Here, we investigated the role of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in the modulation of paclitaxel-induced neuropathic pain. We found that human and mouse neural tissues, including the dorsal root ganglion (DRG), expressed basal levels of PD-1 and PD-L1. During the development of paclitaxel-induced neuropathy, an increase in PD-L1 expression was observed in macrophages from the DRG. This effect depended on Toll-like receptor 4 activation by paclitaxel. Furthermore, PD-L1 inhibited pain behavior triggered by paclitaxel or formalin in mice, suggesting that PD-1/PD-L1 signaling attenuates peripheral neuropathy development. Consistent with this, we observed that the combined use of anti–PD-L1 plus paclitaxel increased mechanical allodynia and chronic neuropathy development induced by single agents. This effect was associated with higher expression of inflammatory markers (Tnf, Il6, and Cx3cr1) in peripheral nervous tissue. Together, these results suggest that PD-1/PD-L1 inhibitors enhance paclitaxel-induced neuropathic pain by suppressing PD-1/PD-L1 antinociceptive signaling.

  • Open Access

    Data from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling

    by Carlos Wagner S. Wanderley, Alexandre G.M. Maganin, Beatriz Adjafre, Atlante S. Mendes, Conceição Elidianne Anibal Silva, Andreza Urba Quadros, João Paulo Mesquita Luiz, Camila Meirelles S. Silva, Nicole R. Silva, Francisco Fabio Bezerra Oliveira, et al.

    Cytotoxic agents synergize with immune checkpoint inhibitors and improve outcomes for patients with several cancer types. Nonetheless, a parallel increase in the incidence of dose-limiting side effects, such as peripheral neuropathy, is often observed. Here, we investigated the role of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in the modulation of paclitaxel-induced neuropathic pain. We found that human and mouse neural tissues, including the dorsal root ganglion (DRG), expressed basal levels of PD-1 and PD-L1. During the development of paclitaxel-induced neuropathy, an increase in PD-L1 expression was observed in macrophages from the DRG. This effect depended on Toll-like receptor 4 activation by paclitaxel. Furthermore, PD-L1 inhibited pain behavior triggered by paclitaxel or formalin in mice, suggesting that PD-1/PD-L1 signaling attenuates peripheral neuropathy development. Consistent with this, we observed that the combined use of anti–PD-L1 plus paclitaxel increased mechanical allodynia and chronic neuropathy development induced by single agents. This effect was associated with higher expression of inflammatory markers (Tnf, Il6, and Cx3cr1) in peripheral nervous tissue. Together, these results suggest that PD-1/PD-L1 inhibitors enhance paclitaxel-induced neuropathic pain by suppressing PD-1/PD-L1 antinociceptive signaling.

  • Open Access

    Supplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling

    by Carlos Wagner S. Wanderley, Alexandre G.M. Maganin, Beatriz Adjafre, Atlante S. Mendes, Conceição Elidianne Anibal Silva, Andreza Urba Quadros, João Paulo Mesquita Luiz, Camila Meirelles S. Silva, Nicole R. Silva, Francisco Fabio Bezerra Oliveira, et al.

    Supplementary Figure from PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling

  • PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling

    by Carlos Wagner S. Wanderley, Alexandre G.M. Maganin, Beatriz Adjafre, Atlante S. Mendes, Conceicao Elidianne. Anibal Silva, Andreza Urba. Quadros, Joao Paulo Mesquita. Luiz, Camila Meirelles S. Silva, Nicole R. Silva, Francisco Fabio Bezerra Oliveira, et al.

    Cytotoxic agents synergize with immune checkpoint inhibitors and improve outcomes for patients with several cancer types. Nonetheless, a parallel increase in the incidence of dose-limiting side effects, such as peripheral neuropathy, is often observed. Here, we investigated the role of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in the modulation of paclitaxel-induced neuropathic pain. We found that human and mouse neural tissues, including the dorsal root ganglion (DRG), expressed basal levels of PD-1 and PD-L1. During the development of paclitaxel-induced neuropathy, an increase in PD-L1 expression was observed in macrophages from the DRG. This effect depended on Toll-like receptor 4 activation by paclitaxel. Furthermore, PD-L1 inhibited pain behavior triggered by paclitaxel or formalin in mice, suggesting that PD-1/PD-L1 signaling attenuates peripheral neuropathy development. Consistent with this, we observed that the combined use of anti–PD-L1 plus paclitaxel increased mechanical allodynia and chronic neuropathy development induced by single agents. This effect was associated with higher expression of inflammatory markers (Tnf, Il6, and Cx3cr1) in peripheral nervous tissue. Together, these results suggest that PD-1/PD-L1 inhibitors enhance paclitaxel-induced neuropathic pain by suppressing PD-1/PD-L1 antinociceptive signaling.


  • Open Access

    Características demográficas e clínicas de portadores de migrânea

    by Ana Heloisa Gomes, Glauce Regina Pigatto, Lívia Assis, Débora Bevilaqua-Grossi, Nivaldo Antônio Parizotto

    A migrânea é uma condição clínica referida como uma perturbação cefalálgica primária, comum e incapacitante, de alta prevalência e que produz impactos socioeconômicos e pessoais elevados. Ela possui manifestações episódicas, com crises recorrentes de cefaleia, apresentando-se com quadro de dor unilateral, pulsátil, de intensidade moderada ou severa. Por ser considerada uma afecção bastante comum e incapacitante, o objetivo desse estudo foi o de caracterizar, demográfica e clinicamente, portadores de migrânea. Esse trabalho faz parte de um estudo clínico duplo-cego, cruzado e randomizado sobre a aplicação de um tratamento com fotobiomodulação em portadores de migrânea. Quarenta e três indivíduos elegíveis, de ambos os gêneros, após uma triagem inicial e uma avaliação com neurologistas, foram randomizados (1:1) e separados no Grupo A e B e preencheram o Questionário de Avaliação da Incapacidade por Enxaqueca (MIDAS), o 12 – Item Allodynia Symptom Checklist (ASC – 12) – Versão Brasileira, e o Diário de Dor (durante um mês). Os resultados da caracterização da amostra mostraram maior ocorrência da migrânea nas mulheres, com homogeneidade em relação à idade, peso, altura, tempo de ocorrência, frequência e intensidade de dor entre os grupos. A náusea, fotofobia, fonofobia e osmofobia foram os fatores predisponentes mais evidentes nas análises realizadas. O MIDAS indicou presença de grau moderado de dor de cabeça em ambos os grupos e o ASC-12 do grupo A indicou presença de alodínia severa e no B, alodínia moderada. Esses dados indicam que a migrânea gera sérios problemas aos seus portadores, os quais interferem consideravelmente na sua qualidade de vida.


  • Low‐Intensity Photobiomodulation Decreases Neuropathic Pain in Paw Ischemia‐Reperfusion and Spared Nervus Ischiadicus Injury Experimental Models

    by Glauce R. Pigatto, Maiara H.S. Quinteiro, Ricardo L. Nunes‐De‐Souza, Norberto C. Coimbra, Nivaldo A. Parizotto

    Background: There is a wide range of animal models available today for studying chronic pain associated with a variety of etiologies and an extensive list of clinical manifestations of peripheral neuropathies. Photobiomodulation is a new tool for the treatment of pain in a convenient, noninvasive way.Objective: The aim of this work is to elucidate the effects of infrared light‐emitting diodes (LEDs) on behavioral responses to nociceptive stimuli in chronic pain models.Methods: Forty‐eight Swiss male mice weighing 25 to 35 g were used. Two chronic pain models, ischemia‐reperfusion (IR) and spared spinal nerve injury, were performed and then treated with infrared LED irradiation (390 mW, 890 nm, 17.3 mW/cm2, 20.8 J/cm2, for 20 minutes). The behavioral tests used were a mechanical hypersensitivity test von Frey test) and a cold allodynia test (acetone test).Results: The results showed that, in the IR model, the infrared LED had a significant effect on mechanical stimulation and cold allodynia on every day of treatment. In the spared nerve injury model, an analgesic effect was observed on every treatment day (when started on the 3rd and 7th days after the surgery). In both models, the effect was abolished when the treatment was interrupted.Conclusions: These findings suggest that photobiomodulation therapy may be a useful adjunct treatment for chronic pain.